CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Dec. 30, 2017	Dec. 31, 2016
Cash Flows from Operating Activities:
Net income	$ 33,692	$ 24,872
Non-cash items:
Depreciation and amortization	66,267	67,531
Gain on divestiture	(8,000)	0
Stock-based compensation expense	7,360	6,608
Provision for losses on accounts receivable and inventory	514	11,398
Impairment of assets	218	3,413
Other non-cash operating activities	398	1,216
Change in operating assets and liabilities:
Change in accounts receivable	8,204	3,878
Change in inventories	17,460	(13,960)
Change in prepaid income taxes	805	868
Change in other assets and other liabilities	17,747	(996)
Change in accounts payable and accrued expenses	18,058	20,333
Net cash provided by operating activities	162,723	125,161
Cash Flows from Investing Activities:
Capital expenditures	(55,696)	(60,517)
Proceeds from divestiture	9,000	0
Proceeds from sale of property, plant and equipment	1,627	1,773
Net cash used in investing activities	(45,069)	(58,744)
Cash Flows from Financing Activities:
Repayment of term loan borrowings	(45,054)	(30,827)
Proceeds from employee stock purchase plan	3,246	3,560
Proceeds from exercise of stock options	33,239	18,278
Net increase (decrease) in short-term loans	579	(40,975)
Net cash used in financing activities	(7,990)	(49,964)
Effect of exchange rates on cash and cash equivalents	2,363	(1,937)
Net Change in Cash and Cash Equivalents	112,027	14,516
Cash and Cash Equivalents at Beginning of Period	139,564	115,123
Cash and Cash Equivalents at End of Period	251,591	129,639
Supplemental Disclosures of Cash Flow Information:
Interest paid	5,684	6,058
Income taxes paid	7,320	5,724
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 5,424	$ 5,081